Lauren A. Kaplanis

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Characterization of on-target adverse events caused by TRK inhibitor therapy”.

Characterization of on-target adverse events caused by TRK inhibitor therapy

Annals of Oncology(2020)10.1016/j.annonc.2020.05.006

N/A

0DataRank · unranked

86 citations

James Flory, Andrew Lin, Michael Offin, Christina J. Falcon, Yonina R. Murciano‐Goroff +16 more

Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.06.008

N/A

0DataRank · unranked

47 citations

Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, Lauren A. Kaplanis, Clare Wilhelm +12 more

Mechanisms of acquired resistance to TRK inhibitors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3104

N/A

0DataRank · unranked

17 citations

Noura J. Choudhury, Alison M. Schram, Ezra Y. Rosen, Yonina R. Murciano‐Goroff, Christina J. Falcon +13 more

Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9080

N/A

0DataRank · unranked

3 citations

Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, Lauren A. Kaplanis, Clare Wilhelm +11 more

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100792

N/A

0DataRank · unranked

3 citations

Rose Parisi, Guilherme Harada, Andrea P. Moy, George Dranitsaris, Jasmine H. Francis +7 more